brain-aging
(2)
NeuroAge Therapeutics
NeuroAge Therapeutics is a San Francisco tech-bio company that measures how old your brain actually is - and tries to make it younger. Founded in 2022 by physician-scientist Dr. Christin Glorioso, the company's flagship NeuroAge Test blends brain MRI, cognitive games, proprietary RNA blood biomarkers, and genetic screening into a single 'brain age' score that aims to flag dementia risk up to 30 years before symptoms appear. The longer-term goal is bolder: small-molecule drugs that reprogram aging neurons back toward a younger state.
Christin Glorioso
Christin Glorioso, MD, PhD, is a physician-scientist and serial entrepreneur who is CEO and co-founder of NeuroAge Therapeutics, a San Francisco brain-health company building AI-powered 'aging clocks' for the human brain. Trained at MIT and the Carnegie Mellon/University of Pittsburgh Medical Scientist Training Program, she spent two decades studying how brains age before leaving academia to turn that research into a diagnostic and drug-development engine. NeuroAge combines MRI brain-volume data, cognitive testing and proprietary RNA blood biomarkers - validated on data from more than 500,000 people - to estimate brain age and dementia risk decades before symptoms. She also founded the nonprofit Longevity Global and led the world's top-ranked US COVID-19 forecasting model in the XPRIZE Pandemic Response Challenge.